← All trials
NCT05303402
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2022
- Primary completion
- Jul 20, 2023
- Completion date
- Oct 20, 2023
- First posted
- Mar 31, 2022
- Last posted
- Jun 27, 2022
- Enrollment
- 400
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorios Hipra, S.A.Lead sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaCollaborator
- AsphalionCollaborator
- Veristat, Inc.Collaborator
- FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.